Neuro-Oncology Clinical Research Coordinator
Lakshita Lopez Lopez is a Neuro-Oncology Clinical Research Coordinator at Children’s Healthcare of Atlanta (CHOA). She is responsible for patient consenting and enrollment, clinical data management and quality assurance for the Children’s Brain Tumor Network (CBTN). Lakshita also oversees various brain tumor clinical research studies and biorepository studies at CHOA. Her responsibilities encompass recruiting, consenting, enrolling, tissue collection and submission of tissue/blood, as well as tracking the enrolled patients for the Children’s Oncology Group (COG).
Before joining CHOA in November 2022, Lakshita Lopez Lopez made significant contributions as a Research Specialist in the Pediatrics Infectious Disease laboratory led by Dr. Ann Chahroudi at Emory University’s School of Medicine. Her impactful work included multiple research studies utilizing non-human primates, with a specific focus on pediatric HIV pathogenesis and cure.
Notably, she has a published work from her time at Emory in December 2022, titled "Elucidating the effects of combination therapy with Venetoclax and IAP inhibitor AZD5582 in SIV-infected, ART-suppressed macaques," which was published in the Journal of Virus Eradication. This study explores the effects of combination therapy on SIV-infected, ART-suppressed macaques, shedding light on potential advancements in HIV cure strategies. Several pending publications further highlight the depth of her contributions in this critical field.
Dedicated to advancing pediatric brain tumor research, Lakshita finds inspiration from committed patients and families. Their shared passion for finding a cure propels her. Motivated by this commitment, she aspires to become a neonatologist, contributing to the field's progress and positively impacting the lives of young individuals affected by brain tumors."
Clinical Research, Neuro-oncology
Children's Healthcare of Atlanta
PP 2.14 – 00162 Elucidating the effects of combination therapy with Venetoclax and IAP inhibitor AZD5582 in SIV-infected, ART-suppressed macaques
Combining the IAP inhibitor AZD5582 with the Bcl-2 inhibitor Venetoclax (ABT199) to reverse latency and enhance clearance of infected cells via apoptosis is a novel approach to cure HIV. In this pilot study, we evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ABT199 with AZD5582 in a nonhuman primate model.
B. Ukhueduan, L. Lopez Lopez, K. Bricker, N. Schoof, S. Vidisha, D. Amir, M. Mavigner, A. Schauer, M.L. Cottrell, A. Chahroudi